Matinas Biopharma (MTNB) Competitors $0.96 -0.08 (-7.98%) As of 11:16 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. DRRX, SNYR, NKGN, BFRG, MRKR, GOVX, PMN, PRPH, LPTX, and MEIPShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), NKGen Biotech (NKGN), Bullfrog AI (BFRG), Marker Therapeutics (MRKR), GeoVax Labs (GOVX), ProMIS Neurosciences (PMN), ProPhase Labs (PRPH), Leap Therapeutics (LPTX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors DURECT Synergy CHC Corp. (Uplisting) NKGen Biotech Bullfrog AI Marker Therapeutics GeoVax Labs ProMIS Neurosciences ProPhase Labs Leap Therapeutics MEI Pharma Matinas Biopharma (NYSE:MTNB) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Do analysts recommend MTNB or DRRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer MTNB or DRRX? In the previous week, Matinas Biopharma and Matinas Biopharma both had 1 articles in the media. DURECT's average media sentiment score of 1.89 beat Matinas Biopharma's score of 0.50 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment Matinas Biopharma Positive DURECT Very Positive Does the MarketBeat Community favor MTNB or DRRX? DURECT received 316 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/ADURECTOutperform Votes31660.89% Underperform Votes20339.11% Which has more volatility & risk, MTNB or DRRX? Matinas Biopharma has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Do institutionals & insiders have more ownership in MTNB or DRRX? 11.8% of Matinas Biopharma shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 4.6% of Matinas Biopharma shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, MTNB or DRRX? Matinas Biopharma has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M4.43-$22.94M-$3.86-0.25DURECT$1.86M11.04-$27.62M-$0.15-4.40 Is MTNB or DRRX more profitable? Matinas Biopharma has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Matinas Biopharma's return on equity of -123.06% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% DURECT -198.58%-300.62%-65.17% SummaryDURECT beats Matinas Biopharma on 7 of the 13 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.87M$6.93B$5.60B$19.86BDividend YieldN/A2.55%5.28%3.83%P/E Ratio-0.208.8527.2335.66Price / Sales4.43256.44417.6544.94Price / CashN/A65.8538.2517.51Price / Book0.226.617.124.85Net Income-$22.94M$143.93M$3.23B$1.02B7 Day Performance9.10%3.84%2.74%1.93%1 Month Performance51.62%11.14%8.94%3.02%1 Year PerformanceN/A4.35%31.59%9.84% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas Biopharma0.9011 of 5 stars$0.96-8.0%N/AN/A$4.87M$1.10M-0.2030Short Interest ↓DRRXDURECT1.2346 of 5 stars$0.53+0.3%N/A-58.6%$16.55M$1.86M-0.8780Positive NewsSNYRSynergy CHC Corp. (Uplisting)3.8205 of 5 stars$1.76flat$10.00+468.2%N/A$16.18M$33.59M0.0040News CoverageNKGNNKGen Biotech0.8519 of 5 stars$0.36+27.6%N/A-76.1%$16.18M$80K-0.07N/AGap DownBFRGBullfrog AI2.0105 of 5 stars$1.71flatN/A-33.2%$16.10M$60K-2.014News CoveragePositive NewsGap UpMRKRMarker Therapeutics4.3028 of 5 stars$1.41-9.6%$13.17+833.8%-51.6%$15.95M$6.59M-1.0660High Trading VolumeGOVXGeoVax Labs3.4482 of 5 stars$1.04+2.0%$11.10+967.3%-26.5%$15.80M$5.59M-0.2810News CoveragePMNProMIS Neurosciences2.3858 of 5 stars$0.48-7.9%$4.50+839.5%-68.7%$15.66MN/A-4.795Gap UpPRPHProPhase Labs1.301 of 5 stars$0.37+1.1%N/A-92.2%$15.52M$5.85M-0.30130Positive NewsShort Interest ↑LPTXLeap Therapeutics2.8248 of 5 stars$0.36-5.2%$4.92+1,271.5%-80.6%$14.86MN/A-0.1940Positive NewsMEIPMEI Pharma1.7026 of 5 stars$2.22-0.9%N/A-17.1%$14.79M$65.30M-0.39100News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies DRRX Alternatives SNYR Alternatives NKGN Alternatives BFRG Alternatives MRKR Alternatives GOVX Alternatives PMN Alternatives PRPH Alternatives LPTX Alternatives MEIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTNB Stock Free MTNB Stock Alerts